1. Vancomycin exerts its bactericidal effect by binding with high affinity to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of peptidoglycan precursor units on the outer surface of the bacterial cell membrane. Which of the following best describes the immediate consequence of this binding?
A) Inhibition of the 30S ribosomal subunit, preventing aminoacyl-tRNA docking and blocking peptide elongation
B) Steric blockade of transglycosylation and transpeptidation, preventing cross-linking of nascent peptidoglycan strands into a mechanically stable cell wall
C) Inhibition of penicillin-binding proteins (PBPs) by covalent acylation of the active-site serine residue, blocking transpeptidation only
D) Disruption of the bacterial cytoplasmic membrane via calcium-dependent pore formation, causing rapid membrane depolarization
E) Inhibition of dihydropteroate synthase, blocking folate synthesis and depriving bacteria of thymidine and purines
ANSWER: B
Rationale:
Vancomycin binds the D-Ala-D-Ala terminus of lipid II peptidoglycan precursors on the outer bacterial cell surface. This steric blockade physically prevents both transglycosylation (polymerization of the glycan backbone) and transpeptidation (cross-linking of adjacent peptide chains), halting the construction of a structurally intact cell wall. Because vancomycin targets the substrate lipid II rather than an enzymatic active site, it is not subject to the PBP mutations that confer methicillin resistance, which is why it retains activity against MRSA.
Option A: Option A is incorrect — 30S ribosomal inhibition is the mechanism of aminoglycosides and tetracyclines, not glycopeptides.
Option C: Option C is incorrect — covalent acylation of PBP serine is the mechanism of beta-lactams; vancomycin does not interact with PBPs at all.
Option D: Option D is incorrect — calcium-dependent membrane depolarization through pore formation is the mechanism of daptomycin, a lipopeptide, not a glycopeptide.
Option E: Option E is incorrect — dihydropteroate synthase inhibition is the mechanism of sulfonamides; it has no relevance to glycopeptide pharmacology.
2. A hospitalist is discussing vancomycin pharmacokinetics with a medical student. The student asks why a patient with severe Clostridioides difficile (C. diff) colitis is receiving oral vancomycin rather than intravenous vancomycin, given that IV vancomycin is used for serious systemic infections. Which of the following best explains the rationale?
A) Oral vancomycin is absorbed from the gastrointestinal tract and achieves higher serum concentrations than IV vancomycin, providing superior systemic coverage
B) Intravenous vancomycin reaches the colonic lumen via biliary excretion and is therefore therapeutically equivalent to oral vancomycin for C. diff colitis
C) Oral vancomycin is a pro-drug that is activated by colonic bacterial enzymes to its active form before being absorbed systemically
D) Oral vancomycin is not absorbed from the gastrointestinal tract and acts entirely within the colonic lumen; intravenous vancomycin does not achieve meaningful intraluminal concentrations and would be ineffective for C. diff colitis
E) Both oral and intravenous routes achieve equivalent intraluminal colonic concentrations because vancomycin undergoes extensive enterohepatic recirculation
ANSWER: D
Rationale:
Vancomycin is not absorbed after oral administration and achieves extremely high intraluminal concentrations throughout the gastrointestinal tract, making it one of the agents of choice for severe or recurrent C. diff infection via the oral route. Conversely, IV vancomycin does not achieve meaningful intraluminal GI concentrations and cannot treat C. diff infection. These are pharmacokinetically separate routes with entirely non-overlapping applications — oral vancomycin acts locally and does not contribute to systemic levels, while IV vancomycin acts systemically and does not reach the colonic lumen in therapeutic concentrations.
Option A: Option A is incorrect — oral vancomycin is not absorbed and produces no systemic levels; using it for systemic infections would be ineffective.
Option B: Option B is incorrect — vancomycin does not undergo significant biliary excretion; IV vancomycin does not reach the colon in therapeutic concentrations.
Option C: Option C is incorrect — vancomycin is not a pro-drug and requires no metabolic activation; it is pharmacologically active as administered.
Option E: Option E is incorrect — vancomycin does not undergo enterohepatic recirculation; the two routes are pharmacokinetically independent and non-equivalent.
3. A pharmacist is reviewing vancomycin therapeutic drug monitoring (TDM) for a patient with MRSA bacteremia. According to the 2019 ASHP/IDSA/SIDP consensus guidelines, which pharmacodynamic target is now the preferred monitoring parameter, and what is the recommended target range?
A) Area under the concentration-time curve over 24 hours to minimum inhibitory concentration ratio (AUC₂₄/MIC) of 400 to 600 mg·h/L, with AUC estimation via Bayesian pharmacokinetic software using two timed serum samples
B) Trough serum concentration maintained between 10 and 15 mcg/mL, measured immediately before the fourth dose at steady state
C) Peak serum concentration of 30 to 40 mcg/mL measured 1 hour after completion of the infusion, targeting bactericidal exposure
D) Trough serum concentration maintained between 15 and 20 mcg/mL as a surrogate for AUC exposure, measured at steady state before any dose
E) Time above the minimum inhibitory concentration (T>MIC) exceeding 70 percent of the dosing interval, analogous to beta-lactam pharmacodynamics
ANSWER: A
Rationale:
The 2019 ASHP/IDSA/SIDP consensus guidelines represent a landmark shift in vancomycin TDM practice, recommending AUC-based monitoring as the preferred method over the prior trough-only approach. The target AUC₂₄/MIC of 400 to 600 mg·h/L (assuming an MRSA MIC of 1 mcg/mL, which covers the vast majority of clinical isolates) is associated with optimal efficacy and lower nephrotoxicity rates. AUC estimation is performed using Bayesian pharmacokinetic software with two timed serum samples to individualize pharmacokinetic parameters.
Option B: Option B is incorrect — a trough target of 10 to 15 mcg/mL is subtherapeutic for serious MRSA infections and is not the current guideline recommendation.
Option C: Option C is incorrect — vancomycin is not a concentration-dependent agent monitored by peak concentration; it follows AUC-dependent pharmacodynamics, not peak-dependent kinetics.
Option D: Option D is incorrect — while trough monitoring with a target of 15 to 20 mcg/mL was the prior standard and remains acceptable when Bayesian tools are unavailable, it is no longer the preferred method; it was associated with excess nephrotoxicity and imprecise AUC surrogacy.
Option E: Option E is incorrect — T>MIC is the relevant pharmacodynamic index for beta-lactams; vancomycin pharmacodynamics are governed by AUC/MIC, not time-dependent killing.
4. A 58-year-old man is admitted with sepsis of unknown source and started empirically on vancomycin. The team debates adding a broad-spectrum beta-lactam for Gram-negative coverage. Which of the following combinations carries significantly higher risk for acute kidney injury (AKI) compared to vancomycin paired with cefepime?
A) Vancomycin plus aztreonam, due to additive tubular toxicity from the monobactam ring structure
B) Vancomycin plus meropenem, due to carbapenem-induced inhibition of vancomycin renal tubular secretion
C) Vancomycin plus piperacillin-tazobactam, due to a synergistic nephrotoxic interaction that significantly increases AKI rates compared to vancomycin with cefepime or other beta-lactams
D) Vancomycin plus ceftriaxone, due to competitive inhibition of albumin binding increasing free vancomycin concentrations
E) Vancomycin plus ampicillin-sulbactam, due to sulbactam-mediated displacement of vancomycin from proximal tubular transporters
ANSWER: C
Rationale:
The combination of vancomycin with piperacillin-tazobactam has been associated with significantly increased rates of acute kidney injury compared to vancomycin alone or with other beta-lactams such as cefepime. This finding prompted widespread reconsideration of the van/pip-tazo combination in empiric regimens, particularly in critically ill patients already at risk for renal dysfunction. The proposed mechanism involves piperacillin-tazobactam impairing renal tubular secretion pathways that normally excrete vancomycin or its nephrotoxic metabolites, though the exact mechanism remains an area of study. This has resulted in many institutions preferring vancomycin plus cefepime over vancomycin plus piperacillin-tazobactam for empiric coverage of mixed infections.
Option A: Option A is incorrect — aztreonam does not carry a clinically significant nephrotoxic interaction with vancomycin; it is generally considered a safe combination and is preferred in penicillin-allergic patients.
Option B: Option B is incorrect — meropenem does not inhibit vancomycin renal tubular secretion and does not carry an elevated AKI risk in combination with vancomycin.
Option D: Option D is incorrect — ceftriaxone does not significantly displace vancomycin from albumin binding, and this is not a recognized clinically significant interaction.
Option E: Option E is incorrect — sulbactam-mediated displacement of vancomycin from tubular transporters is not an established pharmacokinetic interaction; ampicillin-sulbactam does not carry a significant nephrotoxic synergy with vancomycin.
5. During a vancomycin infusion, a patient develops flushing, erythema, and pruritus over the face, neck, and upper torso. Vital signs are stable. The nurse asks the physician whether this represents a true allergic reaction requiring permanent discontinuation of vancomycin. Which of the following best characterizes this reaction and its management?
A) This is an IgE-mediated hypersensitivity reaction that predicts future anaphylaxis; vancomycin must be permanently discontinued and the allergy documented
B) This is complement-mediated angioedema triggered by vancomycin activating the classical complement pathway; antihistamines are ineffective and epinephrine is required
C) This is a dose-dependent immune complex reaction requiring reduction of the total vancomycin dose by 50 percent before restarting the infusion
D) This is a predictable pharmacodynamic effect caused by vancomycin binding directly to mast cell Fc receptors, triggering cytokine-mediated systemic inflammation
E) This is red man syndrome, a rate-dependent non-IgE-mediated reaction caused by vancomycin-induced direct mast cell degranulation and histamine release; it does not predict anaphylaxis and does not contraindicate future vancomycin use; management is slower infusion rate and pretreatment with an H1 antihistamine such as diphenhydramine
ANSWER: E
Rationale:
Red man syndrome (RMS) is an infusion-related reaction caused by vancomycin-induced non-immune mast cell degranulation and direct histamine release, producing the characteristic flushing, erythema, and pruritus predominantly over the face, neck, and upper torso. It is rate-dependent rather than IgE-mediated: slowing the infusion rate substantially reduces or eliminates the reaction. RMS does not predict anaphylaxis and does not contraindicate future vancomycin use. Patients incorrectly labeled as vancomycin-allergic due to RMS are unnecessarily deprived of a critical antibiotic; proper characterization of the reaction type is essential before any allergy designation is applied. Management is pretreatment with diphenhydramine and extension of infusion time to 90 to 120 minutes.
Option A: Option A is incorrect — RMS is not IgE-mediated and does not predict anaphylaxis; labeling it a true allergy and permanently discontinuing vancomycin would be inappropriate and potentially harmful.
Option B: Option B is incorrect — RMS is not complement-mediated angioedema; it does not involve the classical complement pathway, and antihistamines are in fact effective.
Option C: Option C is incorrect — RMS is not a dose-dependent immune complex reaction; it is rate-dependent, and the intervention is slowing the infusion rate, not reducing the total dose.
Option D: Option D is incorrect — while mast cells are involved, vancomycin does not bind Fc receptors; the degranulation is direct and non-immune, and the reaction does not involve cytokine-mediated systemic inflammation.
6. Which of the following correctly describes the pharmacokinetic profile of intravenous vancomycin in a patient with normal renal function?
A) Volume of distribution (Vd) of approximately 0.04 L/kg, primarily confined to the plasma compartment; elimination half-life of 1 to 2 hours via hepatic CYP3A4 metabolism
B) Volume of distribution (Vd) of approximately 0.4 to 1.0 L/kg, reflecting widespread tissue distribution; elimination almost entirely via glomerular filtration, with a half-life of approximately 4 to 8 hours
C) Volume of distribution (Vd) of approximately 5 to 7 L/kg, reflecting extensive intracellular distribution; elimination primarily via hepatic glucuronidation with renal excretion of metabolites
D) Volume of distribution (Vd) of approximately 0.1 L/kg, confined to the extracellular fluid; elimination via a combination of renal tubular secretion and hepatic oxidation in roughly equal proportions
E) Volume of distribution (Vd) of approximately 0.4 L/kg with elimination half-life of 24 to 48 hours in patients with normal renal function due to high protein binding slowing drug removal
ANSWER: B
Rationale:
Vancomycin has an apparent volume of distribution of approximately 0.4 to 1.0 L/kg, reflecting widespread distribution into body fluids and tissues beyond the plasma compartment, including lung, bone, and soft tissue. Protein binding is approximately 50 to 55 percent, predominantly to albumin. The drug undergoes negligible hepatic metabolism; elimination is almost entirely via glomerular filtration (GFR) in the kidney. In patients with normal renal function, the half-life is approximately 4 to 8 hours. Because renal elimination is the dominant clearance pathway, dose and interval adjustments are essential in patients with renal impairment — in end-stage renal disease the half-life can extend to 200 hours or more.
Option A: Option A is incorrect — a Vd of 0.04 L/kg would confine the drug to plasma, which is inconsistent with vancomycin's broad tissue distribution; vancomycin is also not metabolized by CYP3A4.
Option C: Option C is incorrect — a Vd of 5 to 7 L/kg would suggest extensive intracellular or adipose sequestration, which is inconsistent with vancomycin's pharmacokinetic profile; hepatic glucuronidation is not a significant vancomycin elimination pathway.
Option D: Option D is incorrect — while 0.1 L/kg Vd is in the range for daptomycin (not vancomycin), and renal tubular secretion is not a primary vancomycin clearance mechanism.
Option E: Option E is incorrect — the half-life of 24 to 48 hours in normal renal function is grossly inaccurate; this range would correspond to patients with severe renal impairment.
7. A blood culture from a patient who has been on prolonged vancomycin therapy for MRSA bacteremia grows Staphylococcus aureus with a vancomycin minimum inhibitory concentration (MIC) of 6 mcg/mL. This is classified as vancomycin-intermediate S. aureus (VISA). Which of the following best describes the molecular mechanism underlying VISA?
A) Acquisition of the vanA gene complex from vancomycin-resistant enterococcus (VRE) via conjugation, substituting D-alanyl-D-lactate (D-Ala-D-Lac) for D-Ala-D-Ala and eliminating vancomycin binding
B) Upregulation of mprF, which adds lysine to membrane phosphatidylglycerol, increasing positive surface charge and electrostatically repelling vancomycin before it reaches the cell wall
C) Production of a plasmid-encoded D-Ala-D-Ala ligase variant with reduced affinity for vancomycin binding, directly competing with the drug at the peptidoglycan terminus
D) Gradual cell wall thickening driven by point mutations in regulatory genes such as walKR and vraSR, which increases the number of D-Ala-D-Ala peptidoglycan targets that must be saturated before effective cell wall inhibition is achieved
E) Overexpression of VraSR-independent multidrug efflux pumps that actively export vancomycin from the periplasmic space before it can access lipid II targets
ANSWER: D
Rationale:
VISA strains have MIC values of 4 to 8 mcg/mL and emerge through gradual cell wall thickening caused by point mutations in regulatory genes, particularly walKR and vraSR. The thickened cell wall contains an increased number of D-Ala-D-Ala termini that act as decoy targets, binding and sequestering vancomycin molecules in the outer layers of the cell wall before they can reach lipid II at the membrane surface. This effectively reduces the concentration of active drug available to inhibit cell wall synthesis. VISA frequently arises after prolonged vancomycin exposure and may be preceded by heterogeneous VISA (hVISA), a subpopulation phenomenon.
Option A: Option A is incorrect — acquisition of the vanA gene with D-Ala-D-Lac substitution is the mechanism of high-level vancomycin-resistant S. aureus (VRSA), not VISA; VRSA has MIC values above 16 mcg/mL and is rare.
Option B: Option B is incorrect — mprF mutations that increase membrane positive charge are the primary mechanism of daptomycin resistance, not vancomycin intermediate resistance.
Option C: Option C is incorrect — a plasmid-encoded D-Ala-D-Ala ligase variant is not an established VISA mechanism; VISA is chromosomally driven through regulatory mutations affecting cell wall biosynthesis.
Option E: Option E is incorrect — efflux-pump-mediated vancomycin resistance is not a recognized primary mechanism for VISA; vancomycin's large molecular size and hydrophilic character preclude efficient efflux pump transport.
8. A clinical microbiology laboratory reports a Staphylococcus aureus isolate with a vancomycin MIC above 16 mcg/mL, classified as vancomycin-resistant S. aureus (VRSA). Which of the following correctly describes the resistance mechanism and most appropriate management approach?
A) VRSA carries the vanA gene complex acquired from vancomycin-resistant enterococcus (VRE) via conjugation; this gene encodes enzymes that substitute D-alanyl-D-lactate (D-Ala-D-Lac) for D-Ala-D-Ala in peptidoglycan precursors, eliminating vancomycin binding affinity; management requires infectious disease consultation and alternative agents such as linezolid or daptomycin
B) VRSA arises from progressive cell wall thickening through vraSR mutations accumulating to a point where vancomycin is fully excluded from lipid II; management is high-dose vancomycin targeting AUC above 800 to overcome the resistance
C) VRSA overexpresses the mprF gene, coating the membrane surface with positively charged lysyl-phosphatidylglycerol that repels vancomycin; both linezolid and daptomycin are equally ineffective due to cross-resistance
D) VRSA produces a plasmid-encoded beta-lactamase that cleaves the vancomycin glycopeptide scaffold, inactivating the drug before it reaches the cell wall; beta-lactamase inhibitors restore vancomycin activity
E) VRSA develops high-level resistance through efflux pump overexpression combined with outer membrane remodeling; therapy should include a combination of vancomycin and rifampin to suppress pump expression
ANSWER: A
Rationale:
Vancomycin-resistant S. aureus (VRSA), defined by MIC values above 16 mcg/mL, carries the vanA gene complex acquired from VRE through conjugative transfer. The vanA operon encodes enzymes (including VanH, VanA, and VanX) that reprogram peptidoglycan precursor biosynthesis to terminate in D-Ala-D-Lac instead of D-Ala-D-Ala. The ester linkage in D-Ala-D-Lac has approximately 1,000-fold lower binding affinity for vancomycin than the amide linkage in D-Ala-D-Ala, effectively abolishing glycopeptide activity. VRSA is rare but represents an extremely serious clinical event requiring infectious disease specialist consultation and alternative agents including linezolid or daptomycin.
Option B: Option B is incorrect — the progressive cell wall thickening mechanism describes VISA (intermediate resistance), not VRSA; VRSA cannot be overcome with higher vancomycin doses because the binding target has been chemically altered.
Option C: Option C is incorrect — mprF overexpression is the mechanism of daptomycin resistance, not VRSA; furthermore, linezolid and daptomycin retain activity against most VRSA isolates and are therapeutic options.
Option D: Option D is incorrect — vancomycin is not a beta-lactam and has no susceptibility to beta-lactamase cleavage; no enzymatic inactivation of vancomycin by staphylococci has been established.
Option E: Option E is incorrect — efflux pump overexpression does not produce high-level vancomycin resistance in S. aureus; vancomycin's large molecular size and hydrophilic nature preclude meaningful efflux, and rifampin is not indicated for pump suppression in this context.
9. Daptomycin has a mechanism of action entirely distinct from all other antibacterial drug classes. Which of the following correctly describes how daptomycin kills bacteria?
A) Daptomycin binds the D-Ala-D-Ala terminus of peptidoglycan precursors, blocking transglycosylation in a manner analogous to vancomycin but with a lipophilic tail that improves membrane anchoring
B) Daptomycin irreversibly inhibits the 50S ribosomal subunit by binding the 23S ribosomal RNA, preventing peptidyl transferase activity and halting protein synthesis
C) Daptomycin requires calcium (Ca²⁺) for activation; in the presence of physiologic calcium concentrations it inserts its lipophilic tail into the bacterial cytoplasmic membrane and oligomerizes to form ion-conducting channels, causing rapid membrane depolarization that simultaneously arrests DNA, RNA, and protein synthesis by collapsing the transmembrane electrochemical gradient
D) Daptomycin inhibits undecaprenyl pyrophosphate synthase, blocking the recycling of the lipid carrier required to transport peptidoglycan precursors across the cell membrane, thereby starving the cell wall of building blocks
E) Daptomycin inhibits fatty acid synthesis by binding to the FabI enoyl-ACP reductase enzyme, depleting the bacterial cell membrane of essential lipid components
ANSWER: C
Rationale:
Daptomycin requires calcium (Ca²⁺) for activation — in the presence of physiologic calcium concentrations, the drug undergoes a conformational change that enables its lipophilic tail to insert into the bacterial cytoplasmic membrane. It then oligomerizes to form ion-conducting channels that cause rapid membrane depolarization and dissipation of the transmembrane electrical potential. This collapse of the electrochemical gradient simultaneously arrests DNA, RNA, and protein synthesis, producing rapid concentration-dependent bactericidal activity without cell lysis. Because this mechanism targets the cytoplasmic membrane directly rather than a biosynthetic enzyme, cross-resistance with cell wall agents or protein synthesis inhibitors is not expected at the mechanistic level.
Option A: Option A is incorrect — D-Ala-D-Ala binding to block transglycosylation is the mechanism of vancomycin and other glycopeptides; daptomycin does not interact with peptidoglycan precursors.
Option B: Option B is incorrect — 50S ribosomal subunit inhibition via 23S rRNA binding is the mechanism of linezolid and chloramphenicol; daptomycin has no ribosomal target.
Option D: Option D is incorrect — undecaprenyl pyrophosphate synthase inhibition would block lipid carrier recycling, a mechanism associated with bacitracin; this is not daptomycin's mechanism.
Option E: Option E is incorrect — FabI enoyl-ACP reductase inhibition is the mechanism of isoniazid (in mycobacteria) and some novel antibacterials in development; daptomycin does not target fatty acid synthesis enzymes.
10. A patient with hospital-acquired pneumonia has a bronchial lavage culture growing MRSA that is reported as susceptible to daptomycin, linezolid, and vancomycin. The intern proposes using daptomycin because the in vitro susceptibility report shows a low MIC. The attending immediately rejects this choice. Which of the following best explains why daptomycin must not be used for pneumonia despite in vitro susceptibility?
A) Daptomycin does not penetrate alveolar epithelial cells and cannot achieve bactericidal concentrations within pulmonary macrophages where intracellular MRSA resides
B) Daptomycin is specifically contraindicated in pulmonary infections because it activates the complement cascade in the alveolar space, causing eosinophilic pneumonitis as a direct pharmacodynamic effect
C) Daptomycin's large molecular weight prevents passage across the alveolar-capillary membrane after IV administration, resulting in negligible alveolar drug concentrations regardless of dose
D) Daptomycin is renally cleared and achieves subtherapeutic concentrations in bronchopulmonary secretions; only agents with significant biliary excretion achieve adequate pulmonary drug levels
E) Pulmonary surfactant, particularly phosphatidylglycerol, binds daptomycin and prevents its insertion into bacterial membranes, completely abolishing antibacterial activity within the alveolar space; in vitro susceptibility testing does not replicate this inactivation and is therefore irrelevant to the clinical outcome in pneumonia
ANSWER: E
Rationale:
Surfactant components, particularly phosphatidylglycerol, bind daptomycin and prevent its insertion into bacterial membranes, completely abolishing antibacterial activity within the alveolar space. This pharmacodynamic antagonism is absolute: daptomycin must never be used to treat pneumonia regardless of the causative organism's in vitro susceptibility. Standard susceptibility testing is performed in broth media without surfactant and does not replicate pulmonary pharmacodynamics — an isolate reported as daptomycin-susceptible will not respond in vivo if the infection is pulmonary. Linezolid or vancomycin remain the agents of choice for MRSA pneumonia. This surfactant inactivation principle is one of the most clinically consequential facts in antibacterial pharmacology.
Option A: Option A is incorrect — while intracellular penetration is relevant for some pathogens, daptomycin's failure in pneumonia is not caused by inability to penetrate macrophages; it is caused by extracellular surfactant inactivation before the drug reaches any bacterial target.
Option B: Option B is incorrect — eosinophilic pneumonia is a reported paradoxical adverse effect of daptomycin, but it is an immune-mediated toxicity distinct from the surfactant inactivation phenomenon; it does not explain why daptomycin fails bacteriologically against pneumonia.
Option C: Option C is incorrect — daptomycin does distribute into the alveolar space after IV administration; the problem is not a failure of pulmonary distribution but rather inactivation of the drug once it arrives in the surfactant-rich alveolar environment.
Option D: Option D is incorrect — daptomycin's renal clearance mechanism does not preclude pulmonary drug delivery; many renally cleared drugs achieve adequate pulmonary concentrations, and biliary excretion is not a prerequisite for antibiotic pulmonary efficacy.
11. A patient with MRSA bacteremia is started on daptomycin. He is also taking atorvastatin for hyperlipidemia. Which of the following best describes the monitoring requirements and medication management for this patient during daptomycin therapy?
A) Hepatic function tests should be obtained weekly; atorvastatin should be dose-reduced by 50 percent because daptomycin inhibits CYP3A4 and significantly increases statin plasma concentrations
B) Creatine phosphokinase (CPK) should be monitored weekly; daptomycin should be discontinued if CPK rises above five times the upper limit of normal (ULN) with symptoms or ten times the ULN regardless of symptoms; atorvastatin therapy should be suspended during daptomycin treatment because concomitant use increases myopathy risk
C) Serum vancomycin trough concentrations should be checked weekly to ensure daptomycin has not displaced vancomycin from plasma protein binding, thereby increasing free vancomycin toxicity
D) Audiometric monitoring should be performed at baseline and weekly because daptomycin causes concentration-dependent ototoxicity that is potentiated by HMG-CoA reductase inhibitors (statins)
E) No additional monitoring beyond standard metabolic panels is required; the myopathy risk with daptomycin is primarily theoretical and rarely observed at standard clinical doses
ANSWER: B
Rationale:
The principal adverse effect of daptomycin is skeletal muscle toxicity, manifesting as myopathy with elevation of creatine phosphokinase (CPK) and, rarely, rhabdomyolysis with myoglobinuria and acute kidney injury (AKI). CPK should be monitored weekly during therapy, and daptomycin should be discontinued if CPK rises above five times the upper limit of normal (ULN) with symptoms or ten times the ULN regardless of symptoms. Concomitant use of HMG-CoA reductase inhibitors (statins), including atorvastatin, increases myopathy risk and statin therapy should be suspended during daptomycin courses where clinically feasible.
Option A: Option A is incorrect — daptomycin does not inhibit CYP3A4 and does not significantly affect statin plasma concentrations through pharmacokinetic interaction; the concern is pharmacodynamic additive myotoxicity, not a drug-drug PK interaction.
Option C: Option C is incorrect — daptomycin does not displace vancomycin from plasma protein binding; monitoring vancomycin concentrations is not relevant during daptomycin therapy for bacteremia, and these agents are not typically used together.
Option D: Option D is incorrect — ototoxicity is a recognized adverse effect of vancomycin and aminoglycosides, not daptomycin; daptomycin's primary toxicity is skeletal muscle, not cochlear or vestibular.
Option E: Option E is incorrect — daptomycin myopathy and CPK elevation are well-documented, clinically significant adverse effects that occur at standard doses, particularly with longer courses and in patients on concurrent statins; dismissing the monitoring requirement would be clinically unsafe.
12. An infectious disease consultant is evaluating a patient with persistent MRSA bacteremia after 3 weeks of vancomycin therapy. The latest susceptibility report shows a rising vancomycin MIC of 4 mcg/mL (VISA range). The primary team proposes switching to daptomycin as salvage therapy. The consultant expresses concern. Which of the following best explains why daptomycin may also have reduced efficacy in this patient?
A) Daptomycin requires vancomycin pre-treatment to disrupt the outer peptidoglycan layer before it can access the cytoplasmic membrane; prior vancomycin failure means the organism has developed resistance to this priming step
B) Prolonged vancomycin exposure upregulates the mex efflux pump system in MRSA, which simultaneously exports vancomycin and daptomycin, rendering both agents ineffective
C) MRSA strains that develop VISA simultaneously acquire the vanA gene complex, which also encodes a daptomycin-inactivating esterase, directly destroying the lipopeptide before it reaches its membrane target
D) The cell wall thickening that characterizes VISA simultaneously reduces daptomycin's ability to reach and insert into the cytoplasmic membrane; increasing vancomycin MIC tends to parallel increasing daptomycin MIC through this shared physical barrier mechanism — the vancomycin/daptomycin "see-saw" effect — meaning that prior vancomycin exposure may have already compromised daptomycin susceptibility
E) Daptomycin is inactivated by the thickened peptidoglycan layer's D-Ala-D-Ala termini, which act as pseudo-receptor decoys that sequester daptomycin molecules before they reach the cell membrane
ANSWER: D
Rationale:
The "see-saw" effect describes the well-documented clinical phenomenon in which MRSA isolates that develop intermediate vancomycin resistance (VISA) through cell wall thickening simultaneously show reduced daptomycin susceptibility, even without prior daptomycin exposure. The thickened cell wall that traps vancomycin in D-Ala-D-Ala decoy binding also physically impedes daptomycin's access to its target, the cytoplasmic membrane. As the vancomycin MIC rises, the daptomycin MIC tends to rise in parallel. This means that patients with VISA strains arising from prolonged vancomycin therapy may not be reliably salvageable with daptomycin, and susceptibility testing for daptomycin is essential before relying on it for salvage therapy.
Option A: Option A is incorrect — daptomycin does not require vancomycin pre-treatment to access the cytoplasmic membrane; it inserts independently through its calcium-dependent lipophilic tail mechanism.
Option B: Option B is incorrect — the mex efflux system is characteristic of Pseudomonas aeruginosa, not MRSA; MRSA does not use mex efflux pumps, and efflux-based daptomycin resistance is not an established primary mechanism in S. aureus.
Option C: Option C is incorrect — VISA strains do not acquire the vanA gene complex; the vanA-encoding mechanism characterizes VRSA (high-level resistance), and no daptomycin-inactivating esterase encoded by vanA has been identified.
Option E: Option E is incorrect — daptomycin targets the cytoplasmic membrane, not D-Ala-D-Ala termini; while the thickened cell wall creates a physical barrier, the sequestration of daptomycin by D-Ala-D-Ala as pseudo-receptors is not the established mechanism of the see-saw effect.
13. A 45-year-old woman is diagnosed with acute bacterial skin and skin structure infection (ABSSSI) caused by MRSA. She is otherwise healthy, hemodynamically stable, and a candidate for outpatient management. The team considers dalbavancin. Which of the following best describes the pharmacokinetic property that makes dalbavancin particularly useful in outpatient parenteral antibiotic therapy (OPAT) settings?
A) Dalbavancin has an exceptionally long half-life of approximately 346 to 374 hours (roughly 14 to 15 days), enabling a complete treatment course to be administered as a single 1,500 mg infusion or as two doses (1,000 mg followed by 500 mg one week later), avoiding the need for 10 to 14 days of daily IV therapy
B) Dalbavancin is orally bioavailable with approximately 80 percent absorption after oral dosing, enabling a brief IV loading dose followed by a full oral course, eliminating the need for a peripherally inserted central catheter (PICC) line
C) Dalbavancin undergoes rapid hepatic metabolism with a half-life of 4 to 6 hours, but its highly active primary metabolite has a prolonged half-life of approximately 72 hours that maintains therapeutic concentrations after a single loading dose
D) Dalbavancin's half-life of approximately 24 hours with once-daily IV dosing represents an improvement over vancomycin's every-8-to-12-hour requirements, making it practical for daily outpatient infusion clinic visits
E) Dalbavancin requires therapeutic drug monitoring (TDM) similar to vancomycin because its extended half-life creates cumulative toxicity risk with each subsequent dose; TDM targets are trough concentrations above 15 mcg/mL
ANSWER: A
Rationale:
Dalbavancin is a semisynthetic lipoglycopeptide with an exceptionally long half-life of approximately 346 to 374 hours — roughly 14 to 15 days — enabling a complete treatment course for ABSSSI with a single 1,500 mg infusion, or alternatively 1,000 mg followed by 500 mg one week later. This pharmacokinetic profile allows patients to complete a full course of therapy with one or two infusions rather than 10 to 14 days of daily vancomycin, making it particularly attractive for OPAT programs by enabling earlier hospital discharge or avoiding hospitalization entirely. Dalbavancin does not require TDM and has no known clinically significant drug interactions.
Option B: Option B is incorrect — dalbavancin is not orally bioavailable and must be administered intravenously; no oral formulation exists.
Option C: Option C is incorrect — dalbavancin does not undergo significant hepatic metabolism to an active metabolite; its long half-life is a property of the parent compound itself.
Option D: Option D is incorrect — a half-life of 24 hours would still require daily dosing; dalbavancin's true half-life is approximately two weeks, enabling a one- or two-dose total course, not once-daily infusions.
Option E: Option E is incorrect — dalbavancin does not require therapeutic drug monitoring; the absence of TDM requirements is one of the practical advantages over vancomycin that makes it suitable for OPAT use.
14. Oritavancin is distinguished from vancomycin and dalbavancin by possessing a unique triple mechanism of action. Which of the following correctly identifies all three components of oritavancin's mechanism and the clinical consequence that distinguishes it from other glycopeptides?
A) D-Ala-D-Ala binding, inhibition of the 50S ribosomal subunit, and cell wall autolysis induction; the combination produces activity against vancomycin-resistant enterococcus (VRE) by overwhelming multiple resistance pathways simultaneously
B) Inhibition of transglycosylation, inhibition of transpeptidation via PBP2a, and disruption of membrane integrity; the activity against PBP2a explains why oritavancin retains activity against MRSA when vancomycin fails
C) D-Ala-D-Ala binding, inhibition of transglycosylation through a secondary binding site, and disruption of bacterial membrane integrity through its lipophilic tail; this triple mechanism confers partial activity against vanA-expressing vancomycin-resistant enterococcus (VRE) strains, unlike vancomycin and dalbavancin
D) D-Ala-D-Ala binding, calcium-dependent membrane depolarization identical to daptomycin, and inhibition of DNA gyrase; the anti-gyrase activity provides coverage against fluoroquinolone-resistant Gram-positive organisms
E) Inhibition of D-Ala-D-Ala ligase synthesis, disruption of lipid II flippase activity, and membrane cholesterol extraction; the cholesterol extraction mechanism explains its unique activity profile against vancomycin-resistant organisms
ANSWER: C
Rationale:
Oritavancin has a unique triple mechanism of action: D-Ala-D-Ala binding (shared with vancomycin and dalbavancin), inhibition of transglycosylation through a secondary binding site on the peptidoglycan, and disruption of bacterial membrane integrity through its lipophilic tail. This triple mechanism results in rapid concentration-dependent bactericidal activity. Critically, the membrane-disrupting component combined with the transglycosylation inhibition confers partial activity against vanA-expressing VRE strains — organisms that have replaced D-Ala-D-Ala with D-Ala-D-Lac and thus escape vancomycin binding — because oritavancin's secondary mechanisms remain active even when D-Ala-D-Ala binding is abolished. Vancomycin and dalbavancin rely primarily on D-Ala-D-Ala binding and lose essentially all activity against vanA VRE.
Option A: Option A is incorrect — oritavancin does not inhibit the 50S ribosomal subunit; ribosomal protein synthesis inhibition is the mechanism of linezolid and chloramphenicol, not oritavancin.
Option B: Option B is incorrect — while oritavancin does inhibit both transglycosylation and transpeptidation steps, it does not inhibit PBP2a; PBP2a inhibition is a feature of ceftaroline, which is how it retains activity against MRSA.
Option D: Option D is incorrect — oritavancin does not cause calcium-dependent membrane depolarization (that is daptomycin's mechanism) and does not inhibit DNA gyrase; adding fluoroquinolone-like activity to this description is entirely incorrect.
Option E: Option E is incorrect — oritavancin does not inhibit D-Ala-D-Ala ligase (that enzyme is in the van operon biosynthetic pathway), does not act as a flippase inhibitor, and does not extract membrane cholesterol; these mechanisms are fabricated.
15. A patient treated with a single dose of oritavancin for ABSSSI develops atrial fibrillation two days after receiving the infusion and requires anticoagulation. The emergency physician orders a coagulation panel. Which of the following important drug-laboratory interaction must be recognized before interpreting these results?
A) Oritavancin activates platelet thromboxane A2 receptors, causing platelet aggregation that elevates platelet count and shortens bleeding time, falsely suggesting a prothrombotic state
B) Oritavancin is metabolized to a coumarinlike compound that competitively inhibits vitamin K-dependent clotting factor synthesis, causing a true anticoagulant effect that must be accounted for in dosing
C) Oritavancin chelates calcium in the coagulation assay reagents, falsely prolonging all calcium-dependent coagulation tests including prothrombin time (PT) and activated partial thromboplastin time (aPTT)
D) Oritavancin binds thrombin directly in a reversible manner, causing false prolongation of thrombin time only; PT and aPTT are unaffected and can be interpreted normally
E) Oritavancin interferes with activated partial thromboplastin time (aPTT), prothrombin time (PT), and activated clotting time (ACT) assays for up to 120 hours after dosing; these values should not be interpreted as reflecting actual hemostatic status during this window, and alternative coagulation monitoring methods must be used if anticoagulation is required
ANSWER: E
Rationale:
Oritavancin interferes with aPTT, PT, and ACT assays for up to 120 hours after dosing due to its in vitro effects on the assay reagents and clotting cascade components, producing artificially prolonged results that do not reflect the patient's actual hemostatic status. This is a critical practical consideration: a patient who received oritavancin within the previous 5 days and subsequently requires anticoagulation monitoring cannot have their anticoagulation assessed through standard aPTT or PT-based tests. Clinicians must be aware of this limitation and use alternative monitoring methods if anticoagulation is necessary after oritavancin administration. Similarly, telavancin interferes with coagulation assays by the same mechanism.
Option A: Option A is incorrect — oritavancin does not activate platelet thromboxane A2 receptors; it does not cause platelet aggregation or produce a prothrombotic laboratory profile.
Option B: Option B is incorrect — oritavancin is not metabolized to a coumarinlike compound and does not inhibit vitamin K-dependent clotting factor synthesis; it has no true anticoagulant pharmacological effect.
Option C: Option C is incorrect — while calcium chelation is a plausible mechanism hypothesis, the interference is not purely through calcium chelation in reagents; more importantly, the clinical fact is that the interference affects aPTT, PT, and ACT, not merely calcium-dependent tests.
Option D: Option D is incorrect — oritavancin does not bind thrombin directly, and the interference is not limited to thrombin time alone; both aPTT and PT are affected, not just thrombin time.
16. A 32-year-old woman of childbearing potential is admitted with hospital-acquired bacterial pneumonia (HABP) caused by Gram-positive organisms. The team considers telavancin as an alternative to vancomycin. Which of the following safety requirements and precautions apply specifically to telavancin and must be addressed before initiating therapy?
A) A baseline audiogram is required before initiation because telavancin carries a black-box warning for irreversible sensorineural hearing loss that occurs at a higher frequency than with vancomycin
B) A negative pregnancy test must be obtained before initiating telavancin in women of childbearing potential because the drug is teratogenic in animal studies; telavancin also carries a black-box warning for nephrotoxicity occurring at rates higher than vancomycin in some clinical trials, limiting its use to situations where alternatives are unsuitable
C) Baseline coagulation studies must be obtained because telavancin irreversibly inhibits vitamin K-dependent clotting factor synthesis and carries a black-box warning for bleeding complications requiring prophylactic vitamin K administration
D) Therapeutic drug monitoring (TDM) targeting a trough of 15 to 20 mcg/mL is mandatory because telavancin undergoes saturable protein binding with unpredictable free-drug concentrations at standard doses
E) Telavancin requires dose reduction in patients with hepatic impairment because it is primarily metabolized by CYP3A4 and its metabolites accumulate in liver failure; no pregnancy-related precaution is required
ANSWER: B
Rationale:
Telavancin carries two critical safety requirements. First, a negative pregnancy test must be obtained before initiating therapy in women of childbearing potential because telavancin has been shown to be teratogenic in animal studies and its safety in human pregnancy has not been established. Second, telavancin carries a black-box (boxed) warning for nephrotoxicity, which occurs at rates higher than vancomycin in some clinical trials. These toxicity concerns limit its use to situations where alternative agents are unsuitable, such as HABP or VABP caused by Gram-positive organisms where other options have failed or are contraindicated. Telavancin also requires once-daily IV dosing due to its half-life of approximately 8 hours.
Option A: Option A is incorrect — telavancin does not carry a black-box warning for ototoxicity; ototoxicity at rates warranting a boxed warning is more associated with aminoglycosides, and telavancin's primary toxicity warning is nephrotoxicity.
Option C: Option C is incorrect — while telavancin does interfere with coagulation assays (like oritavancin), it does not irreversibly inhibit vitamin K-dependent clotting factor synthesis and does not carry a black-box warning for bleeding requiring vitamin K prophylaxis.
Option D: Option D is incorrect — telavancin does not require therapeutic drug monitoring in the same manner as vancomycin; saturability of protein binding requiring TDM is not an established clinical monitoring requirement for telavancin.
Option E: Option E is incorrect — telavancin does require renal dose adjustment but is not primarily metabolized by CYP3A4; more importantly, the pregnancy precaution is a specific and mandatory requirement that cannot be omitted.
17. A patient with bacterial meningitis caused by MRSA is being treated with intravenous vancomycin. The team questions whether adequate cerebrospinal fluid (CSF) concentrations can be achieved. Which of the following best describes vancomycin's penetration into the CSF?
A) Vancomycin achieves CSF concentrations approximating 80 to 90 percent of simultaneous serum levels because its hydrophilic character allows passive diffusion through the blood-brain barrier at therapeutic serum concentrations
B) Vancomycin does not penetrate the CSF under any circumstances due to its large molecular weight, and intrathecal or intraventricular administration is required for all central nervous system infections
C) Vancomycin CSF penetration is approximately 50 percent of serum concentrations under normal conditions and decreases to near zero with meningeal inflammation due to upregulation of P-glycoprotein efflux at the blood-brain barrier
D) Vancomycin CSF penetration is limited under normal conditions, approximately 10 to 20 percent of serum levels, but improves somewhat with inflamed meninges; this limited penetration means that achieving adequate CSF concentrations for CNS infections requires targeting higher serum levels, guided by CSF concentration monitoring in some cases
E) Vancomycin is actively transported into the CSF by the choroid plexus organic anion transport system, achieving CSF concentrations two to three times higher than simultaneous serum levels during the acute inflammatory phase of bacterial meningitis
ANSWER: D
Rationale:
Vancomycin has limited penetration into the cerebrospinal fluid under normal conditions, achieving approximately 10 to 20 percent of simultaneous serum concentrations. With inflamed meninges, as occurs in bacterial meningitis, penetration improves somewhat because the blood-brain barrier becomes more permeable during acute inflammation. However, even with inflamed meninges, CSF penetration remains substantially lower than serum concentrations, which is why managing vancomycin therapy for CNS infections requires targeting higher serum levels and ideally measuring actual CSF vancomycin concentrations to confirm therapeutic exposure. Intrathecal or intraventricular vancomycin is occasionally used as an adjunct in refractory or device-related CNS infections where systemic dosing alone is insufficient.
Option A: Option A is incorrect — vancomycin's large molecular weight (~1,450 Da) and hydrophilic character are barriers to CNS penetration, not facilitators; 80 to 90 percent CSF penetration would suggest near-complete barrier bypass, which is not the case.
Option B: Option B is incorrect — while CSF penetration is limited, it is not zero; vancomycin does achieve measurable CSF concentrations, particularly with meningeal inflammation; stating that intrathecal route is required for all CNS infections would be an overstatement.
Option C: Option C is incorrect — the relationship is inverted; vancomycin CSF penetration increases (not decreases) with meningeal inflammation; P-glycoprotein upregulation decreasing CNS penetration during inflammation is not an established mechanism for vancomycin.
Option E: Option E is incorrect — vancomycin is not actively transported into the CSF by organic anion transporters; achieving CSF concentrations two to three times serum levels would not occur and is inconsistent with vancomycin pharmacokinetics.
18. Which of the following correctly describes the approved and commonly used dosing strategies for daptomycin across different infection types?
A) Standard dosing for bacteremia and right-sided endocarditis is 6 mg/kg IV once daily; higher doses of 8 to 10 mg/kg/day or greater have been used for more difficult infections such as left-sided endocarditis or osteomyelitis, though these higher doses are not formally FDA-approved; concentration-dependent killing means the pharmacodynamic index is AUC/MIC
B) Standard dosing for all indications is 4 mg/kg IV every 12 hours, similar to vancomycin's every-12-hour regimen; once-daily dosing produces subtherapeutic trough concentrations and is not recommended for serious infections
C) Daptomycin is dosed entirely by weight-independent fixed doses of 500 mg once daily for bacteremia and 1,000 mg once daily for endocarditis; weight-based dosing is not used because protein binding saturates at doses above 400 mg
D) Standard dosing is 1 mg/kg IV every 8 hours for bacteremia, escalated to 2 mg/kg every 6 hours for endocarditis; these low doses reflect daptomycin's narrow therapeutic index and concern for myopathy at higher exposures
E) Daptomycin dosing is determined by minimum inhibitory concentration (MIC)-guided trough monitoring targeting a trough-to-MIC ratio above 10; a starting dose of 3 mg/kg is used and titrated upward based on measured trough concentrations
ANSWER: A
Rationale:
Daptomycin is dosed at 6 mg/kg IV once daily for bacteremia and right-sided endocarditis, which is the standard and FDA-approved regimen for these indications. For more challenging infections such as left-sided endocarditis or osteomyelitis, doses of 8 to 10 mg/kg/day or higher have been used based on clinical experience and pharmacokinetic modeling, though these higher doses carry greater myopathy risk and require more frequent CPK monitoring. Daptomycin demonstrates concentration-dependent killing, and the pharmacodynamic index that best correlates with efficacy is the AUC/MIC ratio — meaning that higher doses administered once daily are more effective than the same total dose given in divided intervals.
Option B: Option B is incorrect — daptomycin is administered once daily, not every 12 hours; every-12-hour dosing would not be consistent with its pharmacodynamic profile or clinical trial design.
Option C: Option C is incorrect — daptomycin is weight-based (mg/kg), not fixed-dose; weight-independent dosing would lead to significant under- or overdosing across body weight ranges.
Option D: Option D is incorrect — doses of 1 to 2 mg/kg would be grossly subtherapeutic; standard dosing begins at 6 mg/kg, and clinical trials establishing efficacy used 6 mg/kg as the minimum for bacteremia indications.
Option E: Option E is incorrect — daptomycin does not use trough-to-MIC ratio as its primary pharmacodynamic target; AUC/MIC is the relevant index, and trough-based dosing titration starting at 3 mg/kg is not standard practice.
19. A patient with MRSA bacteremia requires daptomycin therapy. His creatinine clearance (CrCl) is calculated at 22 mL/min. Which of the following best describes the required pharmacokinetic adjustment?
A) No dose adjustment is necessary because daptomycin is primarily eliminated by hepatic glucuronidation; renal impairment does not significantly affect drug clearance or accumulation
B) The dose should be reduced to 3 mg/kg but the interval maintained at every 24 hours to limit peak concentrations and reduce myopathy risk in renal impairment
C) Because daptomycin elimination is primarily renal and CrCl is below 30 mL/min, the dosing interval should be extended to every 48 hours; standard dose reduction to every-48-hour dosing is used in severe renal impairment, and supplemental doses may be required after hemodialysis sessions
D) Daptomycin should be avoided entirely in patients with CrCl below 30 mL/min because accumulation is unpredictable and no validated dosing regimen exists for this degree of renal impairment
E) The dose should be reduced to 2 mg/kg every 24 hours with intensive CPK monitoring every 48 hours; the reduced dose maintains sub-toxic peak concentrations while allowing adequate AUC accumulation over the treatment course
ANSWER: C
Rationale:
Daptomycin elimination is primarily renal — approximately 78 percent of a dose is recovered unchanged in the urine. In patients with creatinine clearance below 30 mL/min, the standard adjustment is to extend the dosing interval to every 48 hours, maintaining the same dose per administration while reducing the rate of accumulation. Because daptomycin is removed by hemodialysis, patients on intermittent hemodialysis may require supplemental doses after dialysis sessions depending on the membrane permeability and session duration. Protein binding is approximately 90 to 93 percent, so hemodialysis removal is incomplete but clinically significant.
Option A: Option A is incorrect — daptomycin elimination is primarily renal, not hepatic; hepatic glucuronidation is negligible, and renal impairment significantly affects daptomycin clearance and requires dose adjustment.
Option B: Option B is incorrect — reducing the dose to 3 mg/kg every 24 hours would produce lower peak concentrations, which is disadvantageous for a concentration-dependent drug where AUC/MIC drives efficacy; extending the interval rather than reducing the dose preserves the peak-driven concentration-dependent activity.
Option D: Option D is incorrect — daptomycin can be used in patients with CrCl below 30 mL/min; a validated dosing adjustment (every 48 hours) exists and is recommended rather than avoidance.
Option E: Option E is incorrect — a dose of 2 mg/kg every 24 hours would be grossly subtherapeutic; this approach misapplies the adjustment principle and would result in inadequate AUC/MIC.
20. A European clinician asks about teicoplanin compared to vancomycin. Which of the following best characterizes teicoplanin's pharmacology and clinical status?
A) Teicoplanin is FDA-approved in the United States as a first-line alternative to vancomycin for MRSA infections; its mechanism is identical to vancomycin but it offers the advantage of once-daily oral dosing for mild to moderate infections
B) Teicoplanin is an entirely synthetic glycopeptide that acts through D-Ala-D-Lac substitution inhibition; it is approved in the US for VRE infections where vancomycin has failed
C) Teicoplanin has a half-life of approximately 2 to 4 hours, requiring every-6-hour dosing; it is not available in the US but is used in Europe primarily for its lower cost compared to vancomycin
D) Teicoplanin is a first-generation glycopeptide with identical pharmacology to vancomycin including the same half-life, dosing schedule, and TDM targets; the only difference is its approval status, being available in Europe but not the US
E) Teicoplanin is a naturally occurring glycopeptide closely related to vancomycin in mechanism, binding D-Ala-D-Ala to inhibit peptidoglycan synthesis; its half-life of approximately 70 to 100 hours permits once-daily IM or IV dosing after an initial loading regimen; it is not approved in the United States but is widely used in Europe; TDM targets trough concentrations of 15 to 30 mcg/mL for serious infections
ANSWER: E
Rationale:
Teicoplanin is a naturally occurring glycopeptide with a mechanism identical to vancomycin — binding D-Ala-D-Ala termini to inhibit peptidoglycan synthesis — but with a lipophilic side chain that anchors it to the bacterial membrane, improving potency against some strains. Its half-life of approximately 70 to 100 hours permits once-daily intramuscular or intravenous dosing after a loading regimen, a significant pharmacokinetic advantage over vancomycin's every-8-to-12-hour requirements. Teicoplanin is not approved in the United States but is widely used in Europe and other regions. Therapeutic drug monitoring is still recommended, targeting trough concentrations of 15 to 30 mcg/mL for serious infections. Red man syndrome is less frequent with teicoplanin than vancomycin, and nephrotoxicity rates appear somewhat lower.
Option A: Option A is incorrect — teicoplanin is not FDA-approved in the United States, and it is not orally bioavailable; it must be given parenterally (IM or IV).
Option B: Option B is incorrect — teicoplanin is not a synthetic compound; it is naturally derived; it does not act through D-Ala-D-Lac inhibition (that is the vanA resistance mechanism); and it lacks meaningful activity against vanA-expressing VRE.
Option C: Option C is incorrect — teicoplanin's half-life of 70 to 100 hours is one of its distinguishing advantages, enabling once-daily dosing; a 2-to-4-hour half-life is far too short and entirely incorrect.
Option D: Option D is incorrect — the pharmacology is not identical to vancomycin; teicoplanin's substantially longer half-life, different TDM targets, and lower red man syndrome incidence represent meaningful pharmacokinetic and pharmacodynamic differences.
21. A patient presents in septic shock with suspected MRSA bacteremia. The pharmacist recommends an initial vancomycin loading dose before starting the maintenance regimen. Which of the following best describes the rationale and recommended loading dose strategy?
A) A loading dose of 10 to 15 mg/kg is standard and is given to saturate protein binding sites before the maintenance infusion, with the goal of preventing red man syndrome during subsequent doses
B) A loading dose of 25 to 30 mg/kg is recommended for patients with severe sepsis to achieve therapeutic concentrations rapidly; without a loading dose, standard maintenance dosing requires multiple doses before reaching steady-state concentrations, delaying therapeutic exposure in a time-critical setting
C) Loading doses are not recommended for vancomycin because the volume of distribution is too large for a single dose to achieve meaningful tissue concentrations; the priority is establishing a consistent maintenance dosing schedule
D) A loading dose of 40 to 50 mg/kg is used when the target pathogen has a vancomycin MIC of 1 mcg/mL or higher, to achieve an immediate AUC/MIC ratio above 400 from the first dose forward
E) Loading doses of vancomycin apply only to patients on continuous renal replacement therapy (CRRT) because drug clearance in this setting is too rapid for standard maintenance dosing to achieve steady state
ANSWER: B
Rationale:
Loading doses of 25 to 30 mg/kg are recommended for patients with severe sepsis and suspected MRSA infection because vancomycin's pharmacokinetics result in a relatively long time to steady-state with standard maintenance dosing — typically 4 to 5 half-lives, which in a patient with normal renal function takes approximately 20 to 40 hours. In a severely ill patient where therapeutic concentrations are urgently needed, this delay is clinically unacceptable. A loading dose rapidly achieves concentrations within the therapeutic range from the first administration, with maintenance dosing subsequently targeting the AUC/MIC goal. Each infusion must be administered over at least 60 minutes (and preferably longer for large doses) to reduce infusion-related reactions.
Option A: Option A is incorrect — a loading dose of 10 to 15 mg/kg is subtherapeutic for a loading strategy in sepsis; the recommended range is 25 to 30 mg/kg; protein binding saturation is not the rationale for loading.
Option C: Option C is incorrect — while vancomycin's Vd is moderate (0.4 to 1.0 L/kg), loading doses are effective and recommended; stating that loading doses cannot achieve meaningful tissue concentrations is inaccurate and would leave critically ill patients therapeutically underexposed during the initial hours.
Option D: Option D is incorrect — a loading dose of 40 to 50 mg/kg would be potentially toxic, far exceeding recommended ranges, and loading dose selection is not titrated to the MIC of the specific pathogen.
Option E: Option E is incorrect — loading doses are beneficial in all patients with severe sepsis who require rapid therapeutic concentrations; the indication is not limited to CRRT patients.
22. A medical student asks why vancomycin, which is bactericidal against MRSA, has no activity whatsoever against Gram-negative organisms like Escherichia coli or Pseudomonas aeruginosa, even though these bacteria also have cell walls containing peptidoglycan with D-Ala-D-Ala termini. Which of the following best explains this intrinsic resistance?
A) Gram-negative bacteria express an inducible D-Ala-D-Ala ligase variant with 1,000-fold lower affinity for vancomycin, analogous to the vanA resistance mechanism found in vancomycin-resistant enterococcus (VRE)
B) Gram-negative bacteria possess efflux pumps in their outer membrane that actively export vancomycin before it can diffuse through the periplasm to reach the peptidoglycan target
C) Gram-negative bacteria produce a periplasmic vancomycin-inactivating enzyme that cleaves the glycopeptide scaffold before it reaches the peptidoglycan layer, preventing target engagement
D) Vancomycin's large molecular weight of approximately 1,450 Da and hydrophilic character preclude penetration through the size-restricted outer membrane porins of Gram-negative bacteria; the drug cannot reach the periplasmic space where peptidoglycan D-Ala-D-Ala targets are located, making intrinsic Gram-negative resistance a pharmacokinetic rather than a target-based phenomenon
E) Gram-negative bacteria synthesize peptidoglycan terminating in D-Ala-D-Lac rather than D-Ala-D-Ala as a constitutive feature of their cell wall, eliminating vancomycin binding affinity by the same mechanism seen in acquired vancomycin resistance
ANSWER: D
Rationale:
Vancomycin's intrinsic lack of Gram-negative activity is not due to target modification, enzymatic inactivation, or efflux — it is a pharmacokinetic access problem. Vancomycin is a large tricyclic heptapeptide with a molecular weight of approximately 1,450 Da and is highly hydrophilic. Gram-negative bacteria possess an outer membrane that serves as an additional permeability barrier beyond the cytoplasmic membrane. Hydrophilic molecules above approximately 600 to 700 Da cannot efficiently penetrate through the size-restricted outer membrane porins, and vancomycin's mass is more than twice this threshold. The drug is therefore excluded from the periplasmic space entirely and never reaches the peptidoglycan layer where its D-Ala-D-Ala targets reside. This explains why vancomycin retains activity against MRSA (which has no outer membrane) but has zero activity against Gram-negatives despite the presence of a D-Ala-D-Ala-containing cell wall.
Option A: Option A is incorrect — Gram-negative bacteria do not constitutively express a D-Ala-D-Ala ligase variant; the D-Ala-D-Lac substitution seen in VRE is an acquired resistance mechanism encoded by transposable van gene operons, not an intrinsic Gram-negative feature.
Option B: Option B is incorrect — while Gram-negative efflux pumps contribute to resistance against many antibiotics that do manage to enter the cell, vancomycin never penetrates the outer membrane in the first place; efflux is not the primary mechanism of intrinsic Gram-negative resistance to vancomycin.
Option C: Option C is incorrect — no periplasmic vancomycin-inactivating enzyme exists in Gram-negative bacteria; enzymatic inactivation is not the mechanism of intrinsic resistance.
Option E: Option E is incorrect — Gram-negative bacteria do not constitutively produce D-Ala-D-Lac termini; this is an acquired feature limited to organisms carrying vanA or vanB gene clusters, and it is not a constitutive property of Gram-negative cell biology.
This Web-based pharmacology and disease-based integrated teaching site is based on reference materials that are believed reliable and consistent with standards accepted at the time of development.
Possibility of error and on-going research and development in medical sciences do not allow assurance that the information contained herein is in every respect accurate or complete.
Users should confirm the information contained herein with other sources.
This site should only be considered as a teaching aid for undergraduate and graduate biomedical education and is intended only as a teaching site.
Information contained here should not be used for patient management and should not be used as a substitute for consultation with practicing medical professionals.
Users of this website should check the product information sheet included in the package of any drug they plan to administer to be certain that the information contained in this site is accurate and that changes have not been made in the recommended dose or in the contraindications for administration.
Medical or other information thus obtained should not be used as a substitute for consultation with practicing medical or scientific or other professionals.